Chlorothiazide Sodium

CHEMBL1200616 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
317.7 g/mol
LogP
Phase
4

The sodium salt formulation of chlorothiazide allows for intravenous administration in patients unable to take oral diuretics. It shares the thiazide diuretic mechanism and indications of the oral form. Electrolyte monitoring is essential, particularly for potassium and sodium levels during therapy.

Molecular Weight

317.7000 g/mol

TPSA

124.00 Ų

Therapeutic Areas

Mechanism of Action

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]

InChI

InChI=1S/C7H5ClN3O4S2.Na/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5;/h1-3H,(H2-,9,10,11,12,13);/q-1;+1

Molecular Formula

C7H5ClN3NaO4S2

HBD / HBA

1 / 7

Rotatable Bonds

1

Heavy Atoms

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The sodium salt formulation of chlorothiazide allows for intravenous administration in patients unable to take oral diuretics. It shares the thiazide diuretic mechanism and indications of the oral form. Electrolyte monitoring is essential, particularly for potassium and sodium levels during therapy.

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Yes, Chlorothiazide Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200616. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23675744. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.